Velcade Injection 1 mg/vial contains Bortezomib, a proteasome inhibitor used in the treatment of certain types of cancers, primarily multiple myeloma and mantle cell lymphoma. Bortezomib works by disrupting the proteasome pathway, which is responsible for breaking down proteins in cells. By inhibiting this pathway, Velcade causes cancer cells to accumulate defective proteins, leading to cell stress and ultimately apoptosis (programmed cell death). This targeted mechanism allows for effective management of malignant cells while limiting damage to normal cells.

Velcade is often used in combination with other anticancer medications to maximize therapeutic outcomes. It can be administered to newly diagnosed patients as well as those who have relapsed after previous therapies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each vial contains:

• Bortezomib 1 mg

Mechanism of Action

Bortezomib selectively inhibits the 26S proteasome, a cellular complex responsible for degrading unneeded or damaged proteins. In cancer cells, proteasome inhibition leads to:

• Accumulation of misfolded proteins

• Activation of stress pathways

• Induction of apoptosis

This mechanism disrupts the proliferation of malignant plasma cells in multiple myeloma and other cancers, providing targeted anticancer activity.

Indications

Velcade Injection 1 mg/vial is indicated for:

• Multiple myeloma (both newly diagnosed and relapsed/refractory cases)

• Mantle cell lymphoma

• Patients who require combination chemotherapy regimens for hematologic malignancies

It is administered under strict medical supervision by oncologists experienced in chemotherapy.

Dosage and Administration

Velcade is intended for parenteral administration only, either as a subcutaneous or intravenous injection. Dosage depends on the patient’s condition, treatment schedule, and response:

• Administered as directed by an oncologist in a hospital or clinic setting

• Typically given in cycles with rest periods to allow recovery

• Dose adjustments may be required for patients with liver impairment or severe side effects

Benefits of Velcade Injection

• Targets cancer cells through proteasome inhibition

• Effective in managing multiple myeloma and mantle cell lymphoma

• Can be used alone or in combination with other anticancer therapies

• Supports improved survival rates and disease control in hematologic malignancies

Possible Side Effects

While Velcade is an effective cancer treatment, it may cause side effects, some of which require close monitoring:

• Peripheral neuropathy (numbness or tingling in hands and feet)

• Low blood cell counts (anemia, neutropenia, thrombocytopenia)

• Gastrointestinal symptoms (nausea, diarrhea, constipation)

• Fatigue

• Fever or infections

Serious adverse reactions may occur, so regular follow-up and laboratory monitoring are essential.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Only to be used under professional medical supervision

• Monitor for signs of neuropathy, infection, and blood disorders

• Patients should inform their doctor of any liver, kidney, or heart conditions

• Pregnancy and breastfeeding are contraindications unless advised by a specialist

• Ensure proper handling and disposal due to its cytotoxic nature

Storage

Store Velcade Injection in a refrigerator at 2°C–8°C. Do not freeze. Protect from light and use under sterile conditions. Keep out of reach of children.

Velcade Injection 1 mg/vial (Bortezomib) is a vital treatment option for multiple myeloma and mantle cell lymphoma. With precise medical guidance, it provides targeted anticancer therapy, improving disease management and patient outcomes.